Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. ovarenew

OvaRenew

OvaRenew as a first-line therapy in impaired egg quality treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 OvaRenew project word cloud

Explore the words cloud of the OvaRenew project. It provides you a very rough idea of what is the project "OvaRenew" about.

global    helping    intend    line    plan    world    revolutionize    impaired    markets    stem    child    36    services    contracted    investment    complications    egg    manufacturer    pertaining    regulators    disruptive    gmp    trials    close    industry    specialised    combining    genetically    assesment    reproduction    feasibility    women    human    risk    medica    commercialisation    expansion    ovaries    safety    initial    alignement    contract    initiated    elaborated    decreasing    deepest    drastically    administered    performed    expenditures    invasive    ovarian    oocytes    2015    nutritive    novelty    orally    4    9    therapy    practical    potenza    first    substances    worldwide    tackling    business    ip    infertility    cell    industries    phase2    clinical    innovative    woman    ethics    cells    quality    opportunity    dialogue    final    fertility    expensive    protection    ovarenew    procurement    billion    science    assure    grab    invasiveness    solution    strategy    regulatory    27    mio    regulated    transform    health    market    suitable    ltd    rates    prepared    country   

Project "OvaRenew" data sheet

The following table provides information about the project.

Coordinator		 POTENZA MEDICA D.O.O. 

Organization address
address: CESTA CANKARJEVE BRIGADE 18
city: GROSUPLJE
postcode: 1290
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Slovenia [SI]
 Project website http://www.ovarenew.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    POTENZA MEDICA D.O.O. SI (GROSUPLJE) coordinator 50˙000.00

Map

 Project objective

Potenza Medica Ltd. is specialised in the development and commercialisation of innovative fertility products. Our solution is tackling one of the deepest human needs-reproduction. With OvaRenew as a first-line therapy in ovarian infertility, we intend to grab business opportunity to be the first in the world with disruptive fertility solution for women with impaired egg quality. Global fertility services market was in 2015 estimated to be between 27-36 billion € with growth rates of 8-9% in EU and 4% in US. The novelty is in innovative combining of new findings in fertility and nutritive science, which will revolutionize current industry practice. OvaRenew is based on disruptive findings of stem cells in ovaries that are able to transform into oocytes under defined conditions. Those will be initiated through the substances, administered orally. So far, there is no effective and practical strategy available for impaired egg quality. They all are highly invasive with significant health complications, expensive, not focusing in helping woman to produce genetically own child. OvaRenew will enable women with impaired egg quality to produce their own child while drastically decreasing cost and invasiveness of the procedures on one and country health and other expenditures on the other hand. In 2 years (Phase2), OvaRenew can be prepared for global commercialisation. With 1 mio € investment, final product is planned to be introduced on global markets, with focus on developed world. In Phase 1, a feasibility study will be performed with focus on risk assesment and IP protection. While we are operating in one of the most regulated industries, in close dialogue with regulators, we will assure alignement for safety and regulatory requirements such as those pertaining to cell procurement, GMP, ethics and clinical trials. Suitable contract manufacturer will be contracted. Comprehensive business plan will be elaborated to facilitate initial market up-take and worldwide expansion

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVARENEW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVARENEW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More